The Effect of Pentoxyfiline on Hemoglobin and the Dose of Erythropoietin in Anamic Peritoneal Dialysis Patients

Document Type : Original Article(s)

Authors

1 Assistant Professor, Department of Nephrology, Isfahan Kidney Diseases Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Nephrology, Isfahan Kidney Diseases Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Internal Medicine Resident, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Department of Epidemiology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Anemia is one of the major problems of dialysis patients The primary mechanism of anemia in these patients is Erythropoietin insufficient production by kidneys. Often, this kind of anemia is caused by inflammatory reactions. A large number of dialysis patients, despite receiving adequate doses of erythropoietin, are anemic. Therefore it seems the use of a pharmaceutical composition that can control the inflammatory reactions is an appropriate strategy. This study was done to investigate the effect of Pentoxyfilline on hemoglobin level and Erythropoietin dose in these patientsMethods: This study was a clinical trial that performed on anemic peritoneal dialysis patients. Study patients were randomized to two groups of 25 person recipients Pentoxyfilline and control groups. The amount of blood hemoglobin and serum albumin, iron, Total Iron Binding Capacity (TIBC), ferritin and Parathormone (PTH) were measured at the beginning and the end of the study. Collected data were analyzed by SPSS software.Finding: 45 patients were studied (20 cases and 25 controls). The results of this study have not shown the significant differences in hemoglobin and serum albumin levels changes between two groups. According to results of this study the change of erythropoietin dose was not significant in both goups.Conclusions: According to the results, conducted another study with higher sample size and longer time for investigation of the effect Pentoxyfilline is recommended.

Keywords

References

  1. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006
  2. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(Suppl 7): 25-8.
  3. Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report. Behring Inst Mitt 1988; (83): 188-92.
  4. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17(Suppl 1): 48-52.
  5. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993; 78(4): 520-5.
  6. Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 1995; 25(Suppl 2): S20-S22.
  7. Benbernou N, Esnault S, Potron G, Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995; 25(Suppl 2): S75-S79.
  8. Ferraresi I, Bozzini F, Torta D, Frigerio R, Bernasconi C, Agostoni A. In vitro effects of pentoxifylline on hemoglobin affinity for oxygen and electrolytic equilibrium of human blood. Ric Clin Lab 1983; 13(4): 459-65.
  9. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004; 15(7): 1877-82.
  10. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol 1999; 33(2): 121-5.
  11. Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 2008; 9: 8.
  12. Nazemian F, MohammadPoor AH, Naghibi M. The Effect of Pentoxifylline on Hemoglobin levels in Patients with Erythropoietin-resistant Anemia in Hemodialysis Patients. Proceedings of XLIV Congress of the European renal association European dialysis and transplant association (ERA-EDTA). 2007 June 21-24; Barcelona, Spain. p. 360.
Journal of Isfahan Medical School
Volume 28, Issue 115 - Serial Number 115
September and October 2011
Pages 974-979

Files

History

  • Receive Date: 02 March 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics